These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 24488582)

  • 21. Apoptosis may be an early event of progestin therapy for endometrial hyperplasia.
    Amezcua CA; Lu JJ; Felix JC; Stanczyk FZ; Zheng W
    Gynecol Oncol; 2000 Nov; 79(2):169-76. PubMed ID: 11063639
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prospective randomized study comparing the GnRH-agonist leuprorelin acetate and the gestagen lynestrenol in the treatment of severe endometriosis.
    Regidor PA; Regidor M; Schmidt M; Ruwe B; Lübben G; Förtig P; Kienle E; Schindler AE
    Gynecol Endocrinol; 2001 Jun; 15(3):202-9. PubMed ID: 11447732
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Progestin therapy of complex endometrial hyperplasia with and without atypia.
    Reed SD; Voigt LF; Newton KM; Garcia RH; Allison HK; Epplein M; Jordan D; Swisher E; Weiss NS
    Obstet Gynecol; 2009 Mar; 113(3):655-662. PubMed ID: 19300331
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Management of Endometrial Hyperplasia With a Levonorgestrel-Releasing Intrauterine System: A Korean Gynecologic-Oncology Group Study.
    Kim MK; Seong SJ; Kim JW; Jeon S; Choi HS; Lee IH; Lee JH; Ju W; Song ES; Park H; Ryu HS; Lee C; Kang SB
    Int J Gynecol Cancer; 2016 May; 26(4):711-5. PubMed ID: 26905333
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Pregnant rate and pregnancy-relating factors of patients with early endometrial carcinoma and severe atypical hyperplasia of endometrium after fertility-preserving treatment by progestin].
    Cao DY; Yu M; Yang JX; Shen K; Huang HF; Cheng NH; Sun ZY; Deng CY; Yu Q; He FF
    Zhonghua Fu Chan Ke Za Zhi; 2013 Jul; 48(7):519-22. PubMed ID: 24284224
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combined estrogen-progestin pill is a safe and effective option for endometrial hyperplasia without atypia: a three-year single center experience.
    Wang Y; Nisenblat V; Tao L; Zhang X; Li H; Ma C
    J Gynecol Oncol; 2019 May; 30(3):e49. PubMed ID: 30887764
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Regression of endometrial hyperplasia after treatment with the gonadotrophin-releasing hormone analogue triptorelin: a prospective study.
    Grimbizis G; Tsalikis T; Tzioufa V; Kasapis M; Mantalenakis S
    Hum Reprod; 1999 Feb; 14(2):479-84. PubMed ID: 10099998
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prediction of Relapse After Therapy Withdrawal in Women with Endometrial Hyperplasia: A Long-term Follow-up Study.
    Sletten ET; Arnes M; Lysa LM; Moe BT; Straume B; Orbo A
    Anticancer Res; 2017 May; 37(5):2529-2536. PubMed ID: 28476823
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Down-regulation of bcl-2 is a potential marker of the efficacy of progestin therapy in the treatment of endometrial hyperplasia.
    Amezcua CA; Zheng W; Muderspach LI; Felix JC
    Gynecol Oncol; 1999 Apr; 73(1):126-36. PubMed ID: 10094893
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Levonorgestrel-releasing intrauterine system vs oral progestins for non-atypical endometrial hyperplasia: a systematic review and metaanalysis of randomized trials.
    Abu Hashim H; Ghayaty E; El Rakhawy M
    Am J Obstet Gynecol; 2015 Oct; 213(4):469-78. PubMed ID: 25797236
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Levonorgestrel intra-uterine system as a treatment option for complex endometrial hyperplasia.
    Haoula ZJ; Walker KF; Powell MC
    Eur J Obstet Gynecol Reprod Biol; 2011 Nov; 159(1):176-9. PubMed ID: 21741152
    [TBL] [Abstract][Full Text] [Related]  

  • 32. LNG-IUS versus oral progestogen treatment for endometrial hyperplasia: a long-term comparative cohort study.
    Gallos ID; Krishan P; Shehmar M; Ganesan R; Gupta JK
    Hum Reprod; 2013 Nov; 28(11):2966-71. PubMed ID: 23975691
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Assessment of sub-endometrial blood flow parameters following dydrogesterone and micronized vaginal progesterone administration in women with idiopathic recurrent miscarriage: a pilot study.
    Ghosh S; Chattopadhyay R; Goswami S; Chaudhury K; Chakravarty B; Ganesh A
    J Obstet Gynaecol Res; 2014 Jul; 40(7):1871-6. PubMed ID: 25056464
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pathologic features associated with resolution of complex atypical hyperplasia and grade 1 endometrial adenocarcinoma after progestin therapy.
    Gunderson CC; Dutta S; Fader AN; Maniar KP; Nasseri-Nik N; Bristow RE; Diaz-Montes TP; Palermo R; Kurman RJ
    Gynecol Oncol; 2014 Jan; 132(1):33-7. PubMed ID: 24316307
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Endometrial hyperplasia. Risks, recognition and the search for a safe hormone replacement regimen.
    de Lignieres B
    J Reprod Med; 1999 Feb; 44(2 Suppl):191-6. PubMed ID: 11392031
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of oral or intrauterine device-delivered progestin in patients with complex endometrial hyperplasia with atypia or early endometrial adenocarcinoma: a meta-analysis and systematic review of the literature.
    Baker J; Obermair A; Gebski V; Janda M
    Gynecol Oncol; 2012 Apr; 125(1):263-70. PubMed ID: 22196499
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dienogest versus norethisterone acetate in management of endometrial hyperplasia without atypia.
    Girbash EF; Sherif HE; Radwan AM; Abdeldayem HM
    Arch Gynecol Obstet; 2023 Sep; 308(3):947-952. PubMed ID: 37010614
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hormonal inhibition of endometrium for transcervical endometrial ablation--a prospective study with a 2-year follow-up.
    Römer T; Schwesinger G
    Eur J Obstet Gynecol Reprod Biol; 1997 Aug; 74(2):201-3. PubMed ID: 9306119
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Body mass index trumps age in decision for endometrial biopsy: cohort study of symptomatic premenopausal women.
    Wise MR; Gill P; Lensen S; Thompson JM; Farquhar CM
    Am J Obstet Gynecol; 2016 Nov; 215(5):598.e1-598.e8. PubMed ID: 27287687
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Increased natural killer cells and decreased regulatory T cells are seen in complex atypical endometrial hyperplasia and well-differentiated carcinoma treated with progestins.
    Witkiewicz AK; McConnell T; Potoczek M; Emmons RV; Kurman RJ
    Hum Pathol; 2010 Jan; 41(1):26-32. PubMed ID: 19733383
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.